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ABSTRACT 
Background 
The publication of a wrong conclusion from a randomised trial could have disastrous 
consequences. Missing data are unavoidable in most studies, but ignoring the problem may 
introduce bias to the results.  Finding an appropriate way to deal with missing data is of 
paramount importance. We show how the choice of analysis method can impact on the 
conclusion of the trial with regard to the quality of life outcomes. 
Methods 
Various analysis strategies (analysis of covariance, linear mixed effects model) with and 
without imputation were carried out to assess treatment difference in four quality of life 
outcomes in an example clinical trial. 
Results 
Across all four quality of life outcomes, the various analysis approaches provided different 
estimates of treatment difference, with varying precision, using different numbers of 
patients. In some cases the decision about statistical significance differed. The results 
suggested that where possible extra effort should be made to retrieve missing responses. In 
the presence of data missing at random, simple imputation was inappropriate with multiple 
imputation or a linear mixed effects model more useful. 
Conclusion 
Different trial conclusions were obtained for a variety of analysis approaches for the same 
outcome. Collecting as much data as possible is of paramount importance. Careful 
consideration should be taken when deciding on the most appropriate strategy for analysis 
when missing data are involved and this strategy should be pre-specified in the trial 
protocol. Making inappropriate decisions could result in inappropriate conclusions 
potentially leading to the adoption of a clinical intervention in error. 
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Introduction 
 
The randomised controlled trial (RCT) is an important way of evaluating healthcare 
interventions, forming the basis of evidence based medicine [1]. Information gained from 
trials is optimal when the trial dataset is complete or relatively few data are missing. In 
practice this is very difficult to achieve and most trial datasets will contain missing data. 
Missing data are a problem for many different types of outcomes. Ignoring the presence of 
missing data could have major consequences and potentially lead to the publication of a 
wrong conclusion about a particular therapy, which ultimately could impact on clinical 
practice. Follow-up outcome data collected through postal questionnaires are particularly 
susceptible to the problems of missing data as completion cannot be enforced.     
 
The focus of the work presented is quality of life (QoL) outcomes, but the results are 
applicable to the problem of missing data in general. Taking account of missing QoL 
outcome data is of paramount importance as often the reason why the data are missing is 
related to the QoL itself. Patients may forget to fill them in and not return the 
questionnaires, may not be physically or mentally able or perhaps do not receive them 
through being lost in the post.  The missing data mechanism describes the underlying 
reason why missing data have occurred [2]. If missingness relates to the QoL itself then 
this could potentially be important when analysing the trial outcomes. If missingness is due 
to death the implications of this should be considered.   
 
In an effort to tackle the problem of non-returned postal questionnaires some organisations 
now employ a system of reminder questionnaires to help retrieve data that were initially 
missing. The rationale being that sometimes participants need a little prompting and 
receiving a reminder may prompt them to respond, improving the sample size, allowing the 
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study to have sufficient power to make conclusions and not introduce bias through some 
participants being removed from analysis.  
 
A common approach in analysing RCTs is to use a complete case analysis, whereby 
patients with incomplete data are ignored. In recent years the use of imputation has been 
seen as a way of providing a sensitivity analysis for this. Choice between imputation 
methods is often limited to those which are readily available and easy to implement (e.g. 
mean imputation). Recent advances in multiple imputation have caused this to be more 
widely used, but this approach is still considered as a bit of a ‘black box’ by many 
researchers [3]. Many trials (including our example, REFLUX) collect QoL outcome data 
at baseline and several times during follow-up, but only data from the final endpoint are 
analysed. A complete case analysis on the final endpoint ignores any patient without this 
final outcome even though their interim responses may be valuable in deciding between 
treatment options. Using an example trial we aim to investigate the use of alternative 
analysis strategies that utilise all responses and alongside different approaches for dealing 
with missing data show how conclusions about which treatment is best can be affected.  
 
Methods 
Example trial 
The REFLUX trial [4, 5] was undertaken by Centre for Healthcare Randomised Trials, part 
of the Health Services Research Unit at the University of Aberdeen. The aim of this trial 
was to determine the relative benefits and risks of laparoscopic fundoplication surgery as 
an alternative to long term drug treatment for gastro-oesophageal reflux disease (GORD). 
It was a multicentre trial and recruited 357 participants (178 to surgery and 179 to medical 
management) to the randomised part of the trial and 453 to the preference arms. Since we 
are focusing on RCTs the analysis presented throughout relates to the 357 patients 
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recruited to the randomised arms of the trial. The primary outcome was the disease specific 
REFLUX quality of life score with the generic measures of QoL, SF36 and EQ5D as 
secondary outcomes. The REFLUX score ranges from 0 to 100 and was derived from the 
weighted average of six questions covering heartburn, acid reflux, eating and swallowing, 
bowel movements, sleep, and work, physical and social activities [6]. The SF36 provided 
two summary measures – physical summary and mental summary, each measured on 0-
100 [7]. The EQ5D consists of five questions each with a three category response scale, 
resulting in 243 possible health states which are represented by a continuous outcome 
ranging from -0.59 (QoL worse than death) to 1 (best QoL) [8]. For each QoL outcome a 
higher score represents better QoL. The outcomes were assessed at baseline in clinical 
appointment and then via a postal questionnaire at follow up of three and 12 months post 
surgery or at an equivalent time for those being medically managed.  
 
At each follow-up if a participant did not return the questionnaire within two weeks a 
reminder was issued and subsequently a second reminder two weeks later of they had still 
not responded. This generated an extra portion of data that would otherwise have been 
missing. This feature allows us to investigate the impact of the reminder strategy on the 
trial conclusion. Statistical analysis of QoL outcomes involved an analysis of covariance 
(ANCOVA) of the 12 month score adjusting for age, body mass index (BMI), sex and 
when appropriate baseline score and interaction between baseline score and treatment. This 
approach of analysing the final endpoint, ignoring any interim follow-up data has been 
found to be quite common [9].  
 
Pattern and mechanism of missing data 
Missing data occurs in one of two ways: missing items where one or more questions are 
missed from a returned questionnaire and missing forms where the whole questionnaire is 
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not returned. Many validated QoL questionnaires now allow for some missing items and 
scoring algorithms take account of this [7, 10]. This paper deals with the issue of missing 
forms. Within a study with multiple follow-up assessments, participants will display a 
pattern of missing data. If they return all questionnaires they are regarded as providing 
complete data. If they return all questionnaires until a time at which they fail to return 
anymore they display a monotone missing data pattern. An intermittent pattern of missing 
data occurs if a questionnaire is missed but the participant subsequently returns one at a 
later follow-up.  
 
To understand how best to deal with missing data the first step is to determine the missing 
data mechanism. Three mechanisms of missing data were originally presented by Rubin:  
missing completely at random (MCAR), missing at random (MAR) and missing not at 
random (MNAR) [2]. MCAR represents the situation where the probability that an 
observation is missing does not depend on observed or unobserved data. MAR occurs 
when given the observed data, the probability that an observation is missing does not 
depend on unobserved data.  MNAR means that after accounting for the available observed 
data, the reason for data being missing still depends on the unseen observations. It is 
usually impossible to prove that data are or are not MNAR as the data required to establish 
this are by definition missing and unknown [11].   In the context of QoL data, the 
mechanism refers to whether the missingness is somehow related to the QoL [11]. MCAR 
occurs if the reason for missing QoL assessment is entirely unrelated to QoL (e.g. the 
patient moved). When missingness is related to observed QoL (e.g. a previous assessment) 
after conditioning on covariates then the data are MAR. MNAR occurs if missingness is 
dependent on the QoL at the time the assessment is missing as well as on covariates and 
observed data. Previous work has shown that for REFLUX missing data were MCAR or 
potentially MAR [12]. This work utilised the data collected by reminder, pretended it were 
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missing and assessed the missing data mechanism. Undertaking this investigation in this 
way meant it was possible to determine if the reminder data were MNAR (as we did in fact 
know the observed data). Based on this we were able to conclude that potentially the actual 
missing data were most likely MCAR or MAR. This is an important finding when thinking 
about possible options for imputation or analysis, but as previously intimated we still 
cannot strictly rule out MNAR (for the actual missing data, rather than reminder data)  as 
the actual data needed to do so are in fact missing. Perhaps more importantly the reason for 
being missing may depend on unknown factors, information on which is my definition not 
available.  
 
Dealing with missing data 
There are a number of possible methods which could be used to analyse the QoL outcomes 
to determine if there was a treatment difference. The REFLUX trial group used a complete 
case analysis and only used those patients for which baseline and 12 month scores were 
available. This approach utilised only 276 patients (77%) of the total recruited to the trial 
and ignored the data collected at three months.  A further 29 participants provided either 
baseline or both baseline and three month data which could have been utilised. In total 
353/357 (98.9%) participants provided a REFLUX score on at least one of the three 
occasions and all of these participants could be included if a repeated measures approach 
was used. Imputation has the potential to provide a value for each piece of missing data 
depending on the method used. For example, last value carried forward (LVCF) will only 
provide data for all patients if there is at least one value from a previous assessment 
available. This method could not be used for example at three months if the baseline values 
were missing. The more flexible multiple imputation method can potentially overcome all 
missing values depending on what variables are entered into the imputation model. The use 
of covariates which have missing values themselves can limit this process. Thus a number 
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of things have to be considered when deciding on an imputation model: the assumptions 
they make, the data they require and whether it is of benefit to only be able to impute a 
subset of the values that are missing. A number of options for dealing with missing data 
are now described. 
 
(i) Complete case analysis 
The easiest but usually least desirable option is to simply ignore the missing data and carry 
out a complete case analysis.  This potentially removes a large number of people from the 
analysis and is likely to provide a biased result unless the mechanism is MCAR. In this 
paper this approach is implemented firstly on those responses received without reminder 
(referred to as immediate responses). Secondly, those responses collected after the 
participant had been issued with a reminder (referred to as reminder responses) can be 
included to provide a larger number of observations for analysis. 
 
(ii) Imputation 
A second option often considered is the use of imputation, whereby a reasonable 
alternative value is substituted in for one that is missing.  Imputation can occur with a 
single value (simple imputation) or with multiple values (multiple imputation).  Following 
imputation an augmented complete dataset is obtained, on which standard statistical 
procedures can be carried out.  Common simple imputation methods are simple mean 
imputation, LVCF, hot-deck (random selection from observed responses) or regression 
[13]. 
 
The problems associated with simple imputation are well documented [3, 11, 13]. The 
majority of methods assume MCAR and will often underestimate the variances, resulting 
in inappropriate standard errors leading to inappropriate confidence intervals and p-values 
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[3]. Multiple imputation (MI) aims to overcome this problem and the recent developments 
in software mean that it is more readily available to the researcher [14]. MI techniques take 
account of the uncertainty surrounding the missing value and rather than a single value 
imputed, a number of imputations are carried out creating several augmented datasets. 
Each dataset is analysed separately and then the results combined using Rubin’s method 
[15]. 
 
Several methods exist for multiple imputation and some require monotone missingness 
(when a participant drops out the study and provides no further assessments following a 
period of observed assessments).  Regression, predictive mean match or propensity scoring 
can be used [14, 15].  If an intermittent pattern of missingness exists then Markov Chain 
Monte Carlo (MCMC) imputation using an approximate Bayesian bootstrap can be used 
[14]. Further details on multiple imputation can be found elsewhere [14, 15]. 
 
(iii) Model-based strategies 
In the context of longitudinal data it is possible to use model-based strategies such as a 
mixed-effects model to deal with the missing data [17].  This type of modelling assumes 
MAR which is more plausible in the setting of QoL. More complex procedures exist such 
as a selection model, joint mixed effects model and pattern mixture models and these can 
account for MNAR if implemented carefully [11]. All of these methods require strong 
assumptions and these assumptions cannot formally be tested. The model-based strategy 
considered here was that of a linear mixed effects model.  This allowed the interim 
information from intermediary assessments to be included. This approach increases the 
number of participants used in analysis as each can be included if they provide at least one 
QoL assessment (and it does not have to be the assessment of interest). 
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Methods implemented for REFLUX 
Additional data in the REFLUX trial were collected via a reminder system as previously 
described. Not all researchers use such a system so although we have this data for 
REFLUX we will illustrate the use of some methods which would only use the immediate 
responses (with a view to showing having as much data as possible is of benefit). An 
analysis of covariance (ANCOVA) on the final endpoint is applied, but also the use of a 
linear mixed effects model which incorporates the three month data is explored. One 
example of a simple imputation method (LVCF) is applied alongside multiple imputation 
using a predictive mean match model [14]. These approaches were chosen on the basis of 
previous work [18]. In this previous paper a more comprehensive investigation into 
suitable imputation methods was reported. 
 
The methods applied here are as follows: 
1. ANCOVA at 12 months on immediate response data (no reminder responses) 
2. ANCOVA at 12 months on all observed responses (immediate and reminder) – the 
published analysis approach 
3. Last value carried forwards on immediate responses followed by ANCOVA 
4. Last value carried forwards on all observed responses followed by ANCOVA 
5. Linear mixed effects model on immediate responses only at three and 12 months 
6. Linear mixed effects model using all observed responses  
7. Predictive mean match MI model on immediate responses 
8. Predictive mean match MI model on observed responses 
 
Results 
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The REFLUX trial included 357 randomised participants. At the final endpoint (12 
months), 38% responded immediately and a further 51% responded after reminder. This 
gave an overall response rate of 89%. The patient characteristics collected at baseline are 
shown in Table 1. The mean age was 46.3 years and two thirds were male. No obvious 
differences were seen between the two groups which was to be expected since the groups 
were randomised. Table 2 shows the missing data pattern for the REFLUX trial. Just over 
80% of participants returned all three questionnaires. 
 
Where appropriate imputation was carried out, after which each analysis approach outlined 
earlier was implemented for each of the four QoL outcomes. The estimate of treatment 
difference and its 95% confidence interval (CI) are presented for each QoL outcome in 
Figures 1 to 4. By nature of the methods each utilised a different number of patients and 
this information is shown on the figures. For example, ANCOVA of 12 month immediate 
responses for the RQLS used 121 patients, but including the responses received reminder 
this increased to 276 patients. Imputation or use of a repeated measures approach increased 
the number of patients used even further. Some differences occurred between QoL scores 
for the same analysis method due to the problem of missing items within a particular QoL 
instrument contained within the questionnaire. 
 
Reflux specific QoL (RQLS) 
Figure 1 shows the results of the various analysis approaches for the reflux specific QoL 
score (RQLS).  In this situation all the different analysis strategies gave significant 
estimates of treatment difference, with the surgical procedure providing better follow up 
QoL scores than those on medical management. The magnitude of this difference did 
however differ between the analysis strategies, as did the number of participants included 
in the analysis. Within a particular method, the estimate based on immediate data only was 
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always lower than that based on all the observed data. This suggests that ignoring the 
reminder responses, under-estimates the treatment difference and introduces a bias to the 
results.  
 
To our knowledge there is no published information on what magnitude of change on the 
RQLS would represent a clinically significant difference. The confidence interval for the 
smallest treatment difference estimated using LVCF on immediate data included effects of 
less than 0.2 standard deviations (SDs) of the scores. Using the suggestion by Cohen that 
0.2SDs is a small difference, implies that for this study despite statistical significance, we 
cannot rule out clinically insignificant findings [19, 20] 
 
The number of participants used in the analysis also varies between methods by nature of 
what they are. The first method (ANCOVA on immediate responders at 12 months) used 
only 121 (34%) of participants compared to using multiple imputation in addition to all 
observed responses (99%). The only reason this is not 100% under multiple imputation is 
because of some missing covariate data. The repeated measures approach (linear mixed 
effects model) on all responders used 327 (92%) of participants but alongside MI has the 
assumption of MAR which was shown to be likely [12]. 
 
SF12 
The results for the SF12 physical summary score are shown in Figure 2 and SF12 mental 
summary score in Figure 3. The results of the different analysis approaches for the physical 
summary score follow the same pattern as for the RQLS.  All estimates are significant, but 
of different magnitude and precision, using different numbers of participants. The 
estimates using the ANCOVA on all data and that obtained under multiple imputation or 
the linear mixed effects model are similar. Although all statistically significant, the 
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approach chosen may have an impact on clinical significance. Osoba et al., referred to a 
little change on the SF12 as between 5 and 10 units, with 10-20 as moderate change and 
clinical significance was regarded as 10 units [21]. The estimates here are all below five so 
in this instance clinical significance is not affected by the choice of analysis. For the 
mental summary score (Figure 3), each analysis approach yields a non-significant estimate 
of treatment difference, but the magnitude differed and the precision varied between them 
as was seen for the physical summary score.  
 
EuroQoL EQ5D 
The EQ5D is the interesting QoL score for this set of participants as the choice of analysis 
approach did impact on whether a significant difference between treatment groups was 
found. Figure 4 displays the estimates alongside their 95% CIs. LVCF on immediate data 
followed by the ANCOVA and a linear mixed effects model on the immediate data both 
yield statistically significant results (p = 0.005 and p = 0.013 respectively). The remaining 
approaches provide non-significant results (p>0.05) although the linear mixed effects 
model on all available data is borderline (p=0.053). An estimate of the minimally 
important clinical difference for the EQ5D has been found to be 0.074 [22] or the slightly 
higher 0.082 from the more recent paper [23]. In this instance the other method which 
yields a clinically significant difference between the groups is the linear mixed effects 
model on immediate data (estimate = 0.084). Using LVCF on immediate data followed by 
the ANCOVA yielded a statistically significant result but this was not clinically 
significant. This highlights that the choice of analysis approach can generate a different 
result based on statistical significance and clinical significance. 
 
Summary of results 
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Across all four QoL outcomes, the various analysis approaches provided different 
estimates of treatment difference, with varying precision, using different numbers of 
patients.  The main findings were that the use of the additional reminder data was useful 
and definitely recommended where possible. Of the different statistical analysis 
approaches considered and in the presence of missing data at random a linear mixed effect 
model or multiple imputation were preferred. Use of simple imputation is not 
recommended.  In our opinion the most optimal strategy would be to collect as much 
information as possible, through the use of reminders (or alternative data collection 
strategies). Following this a linear mixed effect model or multiple imputation would be 
suitable. 
 
 
Discussion 
 
The aim of this paper was to illustrate (using REFLUX) how different choices of analysis 
methods can impact upon a trial conclusion. Data from three QoL instruments (four 
outcomes) collected at three time points were obtained. Eight different analysis strategies 
were implemented and included the original published ANCOVA, a linear mixed effects 
model, simple imputation (using LVCF)  and multiple imputation (using predictive mean 
match model) followed by ANCOVA. It was found that the choice of method had a 
bearing on the potential trial conclusion.  In this example trial, the conclusion for the 
statistical significance of the primary outcome (RQLS) would not have been affected (all 
results remained statistically significant). However, using the approach from Cohen that 
0.2SDs can be regarded as a small difference the interpretation of the clinical significance 
of the difference between the two treatment groups may have been altered [19, 20]. 
Statistical significance of the SF12 outcomes was not affected by the approach used, but in 
some cases clinical significance was. For the EQ5D outcome, methods differed in clinical 
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and statistical significance. Thus across the four QoL outcomes, the work does highlight 
the fact that you may get a change in conclusion (either statistical significance or clinical 
significance) depending on the choice of analysis method. 
 
Previous work showed that the missing data in REFLUX was either MCAR or MAR 
depending on the QoL outcome or time point [12]. Knowing this suggests that the simple 
imputation methods are likely to provide biased results. Either the linear mixed effects 
model or multiple imputation process would be more appropriate as they have the 
assumption of MAR. 
 
It is common practice now in clinical trials to specify the analysis plan in advance, and this 
type of sensitivity analysis on the trial result should not be undertaken post-hoc. 
Researchers should pre-specify what they plan to do about any potential missing data, to 
prevent a subsequent suspicion that they may have tried various methods of imputation and 
selectively chosen to report the one that gives results most to their liking. This might take 
the form of pre-specifying a number of analyses to act as a sensitivity analysis to the 
primary analysis approach. 
 
The choice between different approaches for missing data can also depend on the amount 
of data missing.  Schulz and Grimes give a general rule of thumb with regard to missing 
data [24]. They suggest that in a trial with less than 5% missing, the bias will be minimal.  
A trial with over 20% missing poses a serious threat to the validity of the study.  In 
between 5% and 20% missing leads to intermediate levels of problems.  This general rule 
can be applied alongside the approaches set out in this thesis.  Imputation is often only 
regarded as a plausible option when the amount of missing data is less than 20%.  
Undertaking imputation with more than 20% missing should be done so with caution, as it 
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is likely that the result of the trial would not be accepted by the research community.  This 
is provided as a guideline and not a rule for all scenarios.   
 
Conclusion 
In conclusion, researchers should carefully consider how best to analyse a study where 
missing data may be an issue. Since the choice of methods may provide different results, 
the methods chosen should be pre-specified in the trial protocol. Ensuring the maximum 
amount of data as possible is used is important. Use of reminders to recover data initially 
missing may be helpful. In addition taking into account all available data (e.g. linear mixed 
effects model) may be of benefit as everyone with at least one assessment can be included 
and the assumption of MAR may be plausible. Excluding some people may introduce bias 
to the results. Imputation is preferred over complete case analysis, as it takes into account 
all participants within the trial. However, if the proportion of missing data is high, 
imputation must be used with great caution and the conclusions from the analysis must be 
regarded as suspect.  
 
Abbreviations 
ANCOVA – Analysis of Covariance; BMI – body mass index; CI – confidence interval; 
EQ5D – EuroQoL EQ5D; GORD- gastro-oesophageal reflux disease; LVCF – last value 
carried forward; MAR – missing at random; MCAR – missing completely at random; 
MCMC – Markov Chain Monte Carlo; MI – multiple imputation; MNAR – missing not at 
random; QoL – quality of life; RCT – randomised control trial; REFLUX - Randomised 
Evaluation oF Laproscopic sUrgery for reflux; RQLS – Reflux specific quality of life 
score; SD – standard deviation; SF12 – Short Form 12. 
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Tables 
 
Table 1: Patient characteristics at recruitment 
 Total Surgical Medical 
 Patient Characteristic (N=357) (N=178) (N=179) 
Baseline questionnaire returned – N (%) 349 (98) 175 (98) 174 (97) 
Age – mean (SD) 46.3 (11.1) 46.7 (10.3) 45.9 (11.9) 
Male – N (%) 236 (66) 116 (65) 120 (67) 
BMI – mean (SD) 28.4 (4.2) 28.5 (4.3) 28.4 (4.0) 
Duration in months of prescribed 
medication for GORD - median(IQR) 32 (15,76) 33 (15,83) 31 (16,71) 
Employment status - N (%)    
Full-time 226 (63) 116 (65) 110 (61) 
Part-time 29 (8) 13 (7) 16 (9) 
Retired 34 (10) 12 (7) 22 (12) 
Other 68 (19) 37 (21) 31 (17) 
Age left full-time education – N (%)    
16 and under 218 (62) 110  (63) 108  (61) 
17-19 years 78 (22) 38  (22) 40  (23) 
20 years + 58 (16) 28  (16) 30  (22) 
Current Smoker – N (%) 86 (24) 46 (26) 40 (22) 
Erosive oesophagitis – N (%) 182 (59) 85 (55) 97 (62) 
Co-morbidity - H. Pylori status – N (%)    
Positive  (subsequently treated) 26 (10) 12 (9) 14 (10) 
Negative (subsequently untreated) 4 (2) 1 (1) 3 (2) 
Negative 148 (55) 75 (56) 73 (54) 
Uncertain 90 (34) 45 (34) 45 (33) 
Hiatus Hernia present – N (%) 196 (59) 94 (57) 102 (60) 
Asthma – N (%) 42 (12) 21 (12) 21 (12) 
Source of recruitment – N (%)    
Retrospective 167 (49) 84 (49) 83 (48) 
Prospective 176 (51) 87 (51) 89 (52) 
 
 
 
Table 2: Pattern of missing data 
 
Pattern N (%) % Baseline 3 months 12 months 
1 290 81.2 - - - 
2 13 3.6 - - x 
3 24 6.7 - x - 
4 4 1.1 x - - 
5 22 6.2 - x x 
6 1 0.3 x - x 
7 1 0.3 x x - 
8 2 0.6 x x x 
- questionnaire returned; x questionnaire missing 
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Figures 
 
Figure 1: Estimates of treatment difference (95% CI) in RQLS at 12 months  
 
 
 
Figure 2: Estimates of treatment difference (95% CI) in SF12 physical summary scores at 
12 months  
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Figure 3: Estimates of treatment difference (95% CI) in SF12 mental summary scores at 12 
months  
 
 
 
Figure 4: Estimates of treatment difference (95% CI) in EuroQoL EQ5D at 12 months 
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